NEW YORK, November 29, 2018 – Levi & Korsinsky, LLP is investigating the sale of Edge Therapeutics, Inc. (“Edge Therapeutics” or the “Company”) (NASDAQGS: EDGE) to PDS Biotechnology Corporation (“PDS”). The transaction is structured as a stock-for-stock transaction; upon completion of the transaction, Edge Therapeutics shareholders will own 30% of the combined company. To learn more about the action and your rights, go to: https://www.zlk.com/mna/edge-therapeutics-inc-2 or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The Edge Therapeutics merger investigation concerns whether the Board of Edge Therapeutics breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether PDS is underpaying for Edge Therapeutics shares, thus unlawfully harming Edge Therapeutics shareholders.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com